asx spotlight series - new york th february 2014 · 2014. 3. 12. · anteo diagnostics limited i...

“Solid commercial progress and growing revenue streams achieved in 2013 enhance

Anteo’s prospects of becoming cash flow positive in CY2014”

Anteo Diagnostics Limited (ASX:ADO)

ASX Spotlight Series - New York 27th February 2014

Presented by Dr. Geoff Cumming Managing Director & CEO

Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 2

Company Snapshot

Anteo Diagnostics Limited (“Anteo”) is an

Australian biotechnology company that

develops, manufactures and

commercialises proprietary surface

coatings for the global healthcare industry.

Board of Directors Mr. Mark Bouris – Non-Executive Chairman Dr. Geoff Cumming – Chief Executive Officer Ms. Sandra (Sam) Andersen – Non-Executive Director Mr. Richard Martin – Executive Director Dr. John Hurrell – Non-Executive Director

Executive Team Dr. Geoff Cumming – Chief Executive Officer Dr. Joe Maeji – Chief Scientific Officer Mr. Richard Martin – Chief Financial Officer Dr. Tina Baumgartner – VP Business Development & Marketing

Corporate Snapshot

ASX ADO

Cash $7.1M

Market Cap. $134

52 week high $0.20

52 week low $0.05

Shares on issue 814.4M

Shareholders 4,414

Top 20 31%

Directors/staff 17%

Major Shareholders

First Cape Mgt Pty Ltd 9.52%

Austcorp 190 Pty Ltd 4.05%

Nimrod Finance Ltd 2.44%


Recent Highlights

Solid commercial progress and growing revenue streams achieved in 2013…

…enhancing the company’s prospects of becoming cash flow positive in CY2014

Feb 2013

Sales partnership agreement with U.S. based One World Lab

May 2013

Sales partnership agreement with Spanish based Gennova Scientific for Europe & Latin America

June 2013

Feasibility agreement with global healthcare company for development of Point of Care device

June 2013

Granted European Patent on Mix&Go

July 2013

Received a 2-year $1.7M grant with Commercialisation Australia from April 2013

November 2013

Heads of Terms signed with BBI Solutions, a global leader in immunoassay development and

manufacturing services


Mix&Go: A Game Changing Product with emerging revenue streams and significant

growth potential

Mix&Go is a specialized universal “glue”:

• uniquely suited for applications in

diagnostics and life sciences

• Forms ultrathin (< 1nm) layers that bond

strongly

• Is gentle and does not damage the activity

of fragile biomolecules

• Improves pathology tests earlier

disease detection

• Reduces cost of test development and

manufacture (faster/less Ab required)

Mix&Go - Universal Surface Coating

Mix&Go is applicable to numerous other

large healthcare related segments, e.g.:

• Separation of proteins and cells

• Drug discovery and

development

• Medical devices

• Drug delivery

Mix&Go is well suited to be the “glue” of choice in a variety of applications and industries outside of

healthcare, e.g. Resources and Cleantech


Undamaged, oriented

Characteristics Benefits

Undamaged, fully functional proteins on surface

Increased performance Less non-specific binding Improved protein stability

Less protein and/or beads required Reduced cost Saves valuable, expensive proteins

Easy and fast to use and manufacture

Improves efficiency Simpler test procedures Manufacturing faster, easier, more scalable

Improved reproducibility Improved accuracy with improved %CV

Characteristics

Vast majority of proteins are non-functional

More protein (Ab) needed

Complicated, time-consuming procedures Expert knowledge needed

Lower sensitivity, LOD, dynamic range

Orientation is random

Proprietary solution: metal polymers

3D structure is damaged

Game Changing Products for Life Sciences


• Development Fees: From $250,000+ per full-time employee

• License Fees: From $150,000 + p.a

• Ongoing Royalties: On sales from products containing Mix&Go

Potential royalty earnings vary depending on the size of the company and the degree of benefit Mix&Go can bring.

Anteo has multiple and recurring revenue streams including:

Value Creation and Capture

Anteo is targeting large and growing healthcare sectors with Mix&Go. The compelling market opportunities are:

• Laboratory Diagnostics: Encompassing the global IVD market valued at $44 billion in 2011, including the

immunoassay sector at $8.8 billion

• Point-of-Care: Expected size of market by 2017 is $38 billion

• Rapid Test Products: Valued at $3.7 billion in 2012

• Life Science R&D: A very large and diverse $1 billion sector

• Bioseparations: Encompassing protein and protein drug manufacturing sector valued at up to $5 billion

Large global healthcare markets underpin revenue growth potential


Anteo has 4 advanced projects and ongoing pipeline development. We expect to close

deals with 10 or more medium to large companies during next 4 years.

Milestones 2014

License and supply agreement with global point-of-care company

Extension of agreement with global lateral flow company

Anteo Mix&Go (AMG) bead and plate products launched in Australia

Pipeline of additional, unique, value-added solutions for the R&D space realised with partners worldwide

Advancing near-term value accretive opportunities that will translate quickly into revenue….

Anteo is commencing its next phase of product development

Anteo filed two sets of patent applications in August 2013. These patents will complement the existing Mix&Go patent

portfolio, and expand the protected areas of application to bioseparations, drug screening, drug delivery and areas

outside the health care industry, e.g., in clean tech and resources sectors.

2014 2015


Paradigm Shift

With Mix&Go magnetic separation can become

reality

• Technically superior solution

• Economically advantageous

Leverage Mix&Go in bioseparations to create

significant long-term revenue streams for Anteo

Current Approach

Chromatography:

• Time consuming

• Expensive

• Hard to automate

• Capacity constraints

Alternative

Magnetic separation:

• Technically superior

• Currently unaffordable

Large Opportunities

• Protein and protein drug manufacturing: $3-

5B

• Vaccine manufacturing: $620M in 2015

• Stem cell therapy market,: $1 B, CAGR 30%

Bioseparation – Anteo’s Next Opportunity


• Biomaterials/Blood banking

• Medical devices

• High-throughput drug screening

• Cleantech

• Mining

• Others??

Anteo’s Opportunities


Anteo’s Keypoints

Mix&Go is a proprietary platform technology with broad applicability in

diagnostics, life sciences, bioseparations and beyond

Mix&Go is proven licensed and gaining significant traction in commercial

markets

Mix&Go success means Anteo is becoming cash flow positive

Strong near term value drivers

Focus on diagnostics and life sciences with expansion into bioseparations

provides Anteo significant revenue opportunities

Strong leadership - Board and management team in place to drive growth

Global team, resources and network to capitalise on growth opportunity


Contact Information

Thank you very much for your interest in Anteo Diagnostics

For more information please contact:


Forward Looking Statement

The purpose of the presentation is to provide an update of the business of Anteo Diagnostics (ASX:ADO). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Anteo and should not be relied upon as an independent source of information. Please contact Anteo and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Anteo Diagnostics Ltd’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Anteo’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by Anteo Diagnostics Limited. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

asx spotlight series - new york th february 2014 · 2014. 3. 12. · anteo diagnostics limited i...

Documents